[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
HIV resistance to nucleoside analogues such as zidovudine (AZT) is to date a source of concern, even if its clinical significance is yet to be determined. Phenotypic and genotypic data concerning HIV resistance will be presented, then the potential benefits of nucleoside combinations will be discussed.
Pépin
J M
JM
Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France.
Simon
F
F
Brun-Vezinet
F
F
D000212:Acyclovir / Q000494:pharmacology; D016049:Didanosine / Q000494:pharmacology*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D017245:Foscarnet / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D012254:Ribavirin / Q000494:pharmacology*; D016047:Zalcitabine / Q000494:pharmacology*; D015215:Zidovudine / Q000494:pharmacology*
D017245:Foscarnet; D012254:Ribavirin; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine; D000212:Acyclovir
La résistance des virus de l'immunodéficience humaine (VIH) aux analogues nucléosidiques est-elle une indication à leur association?